register

News - MedTech & Diagnostics

Stryker announces fellowships for medtech partner projects

Health Industry Hub | January 17, 2022 |

MedTech News: Stryker announced two of its partner research projects have secured fellowship funding from the Australian government’s Researcher Exchange and Development within Industry (REDI) program.

Both 12-month fellowships will focus on the development of high-value, patient-specific biomedical implants manufactured by 3D printing at the point of care. The collaboration with Stryker will allow the fellows to combine their knowledge with unparalleled access to Stryker’s industry experts, leading technology, and global R&D ecosystem.

“I am very proud that Stryker is once again able to demonstrate its commitment to bringing R&D activity to Australia. The REDI initiative and the R&D Lab are important investments into Australia’s future as a hub for
medtech innovation, and I would like to thank the federal government for funding these fellowships,” said Maurice Ben-Mayor, President of Stryker South Pacific.

The first REDI project, led by Dr Ali Dehghan-Manshadi from the University of Queensland (UQ), will focus on the elimination of post-processing steps currently required for 3D printed metal implants, by manipulating the properties of metal powders with the ultimate goal of delivering a “use as built” biomedical implant. Dr Dehghan-Manshadi will experience first-hand the key decisions that drive commercial success in the manufacturing process; the critical components of an agile global supply chain; and the factors that can influence the decision to commercialise high-value, low-volume products for a global medtech company.

The second project will allow Dr Marie-Luise Wille from Queensland University of Technology (QUT) to focus on optimising the current workflow that exists for the patient journey from CT/MRI imaging to implant. At present this process is non-standardised and contains multiple, time-consuming iterations. Addressing the workflow issue will deliver outstanding value for patients and significantly reduce the time to treatment. In addition, the fellowship will deliver extensive exposure to the medical technology sector, both in Australia and overseas, providing unique access to industry-based knowledge and skills.

The announcement continues Stryker’s commitment to R&D in Australia, following the Queensland government’s recent decision to jointly fund Stryker’s state-of-the-art R&D Lab at the Herston Health Precinct on the Royal Brisbane and Women’s Hospital campus.

Slated to open in mid-2022, Stryker’s R&D Lab is a partnership project with QUT, UQ, Metro North Hospital and Health Service, and Queensland Health to drive ground-breaking domestic research that focuses on data science, robotics, infection control and advanced manufacturing.

“Queensland researchers are leading the way – in large part due to the passion our academic partners have invested in pursuing a 3D printing and additive manufacturing capability here in Australia.

“I would also like to congratulate both Dr Deghan-Manshadi and Dr Wille for their extraordinary work. I can say with great confidence that Stryker teams across the globe are looking forward to working cooperatively with them to advance their research and demonstrate the ability of REDI Fellows to foster innovation and improve patient outcomes,” Ben-Mayor concluded.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.